1、ADC?(HLT)?2022?9?Happy Life TechADC?ADC?ADC?/?ADC?/?ADC?XDCADC?ADC?ADC?ADC?C CO ON NT TE EN NT TS S?ADC?版权 2022 HLT 保留所有权利Happy Life Tech版权 2022 HLT 保留所有权利?ADC?HER2?Trop2?Nectin4?EGFR?CD33?CD30?CD22?CD79b?CD19?BCMA?ADC?ADC?研?ADC?ADC?ADC?ADC?mAb?mAb?的?ADC?ADC?的?ADC?Signal?Transduct Target?Ther.?2022?

2、;7(1):93.Happy Life Tech版权 2022 HLT 保留所有权利?I Ig gG G?屓?屗 IgG?Fc?I Ig gG G1 1?I Ig gG G4 4?研?尰?屓?导?尰?P Pr ro ob bo od dy y-d dr ru ug g c co on nj ju ug ga at te e(?P Pr ro ob bo od dy y?尲尲)?F Fr ra ag gmme en nt t-d dr ru ug g c co on nj ju ug ga at te e(?O Op pt ti iL Li in nk kT TMM?尲尲)?A AD DC C?

3、尰尰?ADADC C?尲尲?尲尲?尽尽?PrPro obobod dy y C Cytyto ommX X?MaMas sk ki in ng g p pe ep pt ti id de e?尰尰?onon-tatar rg ge et t?offoff-tutummo or r?的的?的的?OpOpt ti iL Li in nk kTMTMAnAnt ti ik ko or r?scscF Fv v 去去?模模?屟屟?PKPK?的的?CMCMC C?DADAR RG G-MAMAB B L LI IB BR RA AR RY Y SoSor rr re en nt to o?mAmAb b

4、?尰尰?10101616?尰尰?POPOT TE EL LL LI IG GE EN NT T BiBioWoWa a?N N-?FcFc 尉尉?ADADC CC C?COCOMMP PL LEGENEGENT T KyKyowowa a KiKiri rin n?IgIgG3G3?IgIgG1G1?尰尰?IgIgG1G1?屗屗?CDCDC C?EFEFECTECT ZyZymme ew wo or rk ks s?FcFc?CHCH2 2?尊尊?模模?导导?X Xp pr re es ss s C CFF SuSut tr ro oBiBiophaopharmrma a?屓屓?尰尰?g/g/

5、L L?ISBN:?9783319781549?屍?尽?HLT?P Pr ro ob bo od dy y-d dr ru ug g?c co on nj ju ug ga at te eHappy Life Tech版权 2022 HLT 保留所有权利?2 20 0?A AD DC C?A Au ur ri is st ta at ti in n?D DN NA A?I I?D Dx xd d?去去?去去?R RN NA A?A AD DC C?A AD DC C?毒素前常毒素扰围观蛋聚合进抑制有丝分裂Auristatine及其衍物MMAE,MMAF美登素衍物DM1,DM4对细胞 DNA 造

6、成损伤导致 DNA双链断裂卡霉素抑制 DNA 拓扑异构酶活性喜树碱及其衍物Dxd，SG38影响 DNA 结构PBD新型毒素分凋亡诱导剂RNA 剪切抑制剂烟酰胺磷酸核糖基转移酶抑制剂转录抑制剂?2020.?ISBN:9781788018456,?J?Cell?Physiol.?2020?Jan;?235(1):31-64.?HLT?A AD DC C?A AD DC C?Happy Life Tech版权 2022 HLT 保留所有权利?ADC?A AD DC C?ADC?ADC?研?DAR?ADC?DAR?2022.?ISBN?9781839165153?HLT?A AD DC C?A AD

7、DC C?A AD DC C?A AD DC C?Happy Life Tech版权 2022 HLT 保留所有权利?ADC?ADC?&?ADC?ADC?ADC?ADC?1?ADC?HER2?HER2?ADC?A AD DC C(B Bi ip pa ar ra at to op pi ic c A An nt ti ib bo od dy y D Dr ru ug gC Co on nj ju ug ga at te es s)?A AD DC C?A AD DC C(B Bi is sp pe ec ci if fi ic c A An nt ti ib bo od dy y D Dr r

8、u ug g C Co on nj ju ug ga at te es s)?2?A AD DC C?的的?A AD DC C?Creative?biolabs?ISBN?9783319781549?HLT?双特异性抗体双特异性抗体&双表位抗体双表位抗体ADADC C双特异性双特异性 ADADC C&双表位双表位 ADADC C?A AD DC C?A AD DC CHappy Life Tech版权 2022 HLT 保留所有权利?ADC?ADC?ADC?D Du ua al l-p pa ay yl lo oa ad ds s A An nt ti ib bo od dy y D Dr r

9、u ug g C Co on nj ju ug ga at te es s?MMAE?MMAF?HER2 ADC?A AD DC C?模模?ADC?Nat?Commun?.?2021?Jun?10;12(1):3528.?A AD DC C?A AD DC C?Happy Life Tech版权 2022 HLT 保留所有权利XDC?岔?尰?封封?尽尽?-?(Antibody-radionuclide conjugate?ARC)Ibritumomab tiuxetan?Spectrum Pharmaceuticals?anti-CD20?屓?屓?90Y?屟B?封?-?(Antibody-ph

10、otosensitizer conjugate?APC)Cetuximab sarotalocan?Rakuten Medical?IRDye700DX?24?屜?EGFR?屜?导?-?(Antibody-exotoxin conjugate?AExC)Moxetumomab pasudotox?AstraZeneca?anti-CD22?Fv?38kDa?屓?屲屜?-?屓?(Antibody-biopolymer conjugate?ABC)KSI-301Phase IIIKodiak Sciences?anti-VEGF?屓?屓?尰?屗?wAMD?DME?DR?-?(Antibody-en

11、zyme conjugate?AEC)L-DOS47Phase IIHelix Biopharma?anti-CD66c?屟?-?(Immune stimulating antibody conjugate?ISAC)BDC-1001Phase I/IIBolt Therapeutics?anti-HER2?TLR7/8?HER2?-?(Antibody-cell conjugate?ACC)ACE1702Phase IAcepodia?anti-HER2?off-the-shelf NK?屟?封?HER2?-?(Antibody-oligonucleotide conjugate?AOC)A

12、OC 1001Phase IIAvidity Biosciences?屟TfR1?屟?siRNA?DMPK?mRNA?1?-?(Antibody degrader conjugates?ADeC)ORM-5029Phase IOrum Therapeutics?Payload?ADC?PROTAC?-?(Small molecule-drug conjugate,SMDC)PEN-866Phase I/IIaTarveda TherapeuticsHSP90?屟?-1?SN-38?-?(Peptide-drug conjugate,PDC)BT1718Phase I/IIaBicycle Th

13、erapeuticsMMP-14?屟?尰妥?DM1?-?(Aptamer drug conjugate?ApDC)Optimer?尲?Aptamer Group?研?&?Aptamer?Optimer?屍?siRNA?-?(Virus-like-particle drug conjugate,VDCs)AU-011Phase IIAura Biosciences?HPV?VLP?HSPG?屓?IRDye700DX?屜?尽?HLT?Happy Life Tech版权 2022 HLT 保留所有权利ADC?2022?6?ADC?4 46 63 3?14?2?III?16?II?66?I?148?1

14、2?205?ADC?I I?ADC?ADC?435?9 93 3.9 95 5%?1.73%?的?14?ADC?7?7?I I?I I/I II I?I II I?I II I/I II II I?I II II I?1 18 86 6?9 9?1 13 32 2?3 31 1?3 31 1?3 3?9 9?2 21 14 44 43 35 5?5?0?0?0?2?0?1?0?08?20?1?0?0?0?0?0?0?2?2?0?0?0?0?0?00?0?2?0002000002AL?0010000001?1?0?0?0?0?0?0?0?0?1?HLT?A AD DC C?

15、13135352 214142 21414临床前临床前申报临床申报临床I I 期临床期临床I/II I/II 期临床期临床II II 期临床期临床II/III II/III 期临床期临床III III 期临床期临床申请上市申请上市批准上市批准上市?A AD DC C?205205Happy Life Tech版权 2022 HLT 保留所有权利ADC?ADC?副?ADC?Xenikos/HenogenT-GuardPhase?III?anti-CD3?mAb?anti-CD7?mAb?A?ADC?(aGVHD)?AbbvieABBV-3373Phase?II?anti-TNF?TNF?Abbv

16、ieABBV-154Phase?II?anti-TNF?TNF?GenentechDSTA4637SPhase?I?THIOMAB?IgG1?dmDNA31?SilverbackSBT8230?anti-ASGR1?TLR8?ASGR1?HSCT?MagentaMGTA-117Phase?I/II?anti-CD117?CD117?(HSCT)?HSCT?AL?Sorrento/?STI-6129Phase?I?CD38?duostatin-5?CD38?SilverbackASGR1-TGFR1?anti-ASGR1?TGF?R?ASGR1?TGF?clinicaltrials?HLT?Ha

17、ppy Life Tech版权 2022 HLT 保留所有权利?cut-off?ADC?A AD DC C?Trastuzumab Deruxtecan(Enhertu)?Sacituzumab Govitecan(Trodelvy)?A AD DC C?A AD DC C?Enhertu?Kadcyla?ADC?B Bi io omma ar rk ke er r?c cu ut t-o of ff f?Enhertu?H HE ER R2 2?的?H HE ER R2 2-l lo ow w?Destiny-Breast 06?H HE ER R2 2 u ul lt tr ra al l

18、o ow w?1 1?H HE ER R2 2 I IH HC C?0 0?HER2?CA?Cancer?J?Clin?.?2022?Mar;72(2):165-182.?HLT?A AD DC C?O OR RR R?Enhertu?H HE ER R2 2?Happy Life Tech版权 2022 HLT 保留所有权利?ADC?histology-agnostic?ADC?ADC?histology-agnostic?(1)?研研?(2)?(3)?b bi io omma ar rk ke er r?(4)?I?European Journal of Cancer 171(2022)2

19、5e42?HLT?Happy Life Tech版权 2022 HLT 保留所有权利?ADC?屓?屓屓?屗屗?封?封?HER2-ADC?屓?PD-1?尰?ADC?尰?屓?ADC?屓?导?尰?ADC?屓?ADC?屓?(1)?屟屟 V VE EG GF F?尼尼?尊?ADC 屟?ADC?2?尰?-?屓?A AD DC C-?屓屓?專 ADC?3?A AD DC C?尰尰?屓屓?尰?4?/?尰?ADC?Nat Rev Clin Oncol.2021 Jun;18(6):327-344.HLT?Happy Life Tech版权 2022 HLT 保留所有权利?CDMO、CRO公司中国研发型公司的发与突破ADC?ADC?ADC?的?ADC?ADC?ADC?ADC?ADC?XDC?ADC?ADC?biomarker cut-off?ADC?ADC?CA?Cancer?J?Clin?.?HLT?Happy Life Tech??35?9?版权 2022 HLT 保留所有权利Happy Life TechThank?You?!Happy Life Tech